A5087100639- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- ECG Monitoring and Analysis
- Neurological disorders and treatments
- Heart Failure Treatment and Management
- Infective Endocarditis Diagnosis and Management
- Cardiac Valve Diseases and Treatments
- Phonocardiography and Auscultation Techniques
- Cardiac Structural Anomalies and Repair
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac tumors and thrombi
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular Syncope and Autonomic Disorders
- Non-Invasive Vital Sign Monitoring
- Cardiovascular Function and Risk Factors
- Advanced MRI Techniques and Applications
- Central Venous Catheters and Hemodialysis
- COVID-19 and healthcare impacts
- Acute Ischemic Stroke Management
- Wireless Body Area Networks
- Cardiac, Anesthesia and Surgical Outcomes
- Muscle activation and electromyography studies
Agaplesion Markus Hospital
2024
Cleveland Clinic
2024
Bon Secours Heart & Vascular Institute
2016-2024
ATP Clinical Research (United States)
2024
Arkansas Biosciences Institute
2016-2024
The Arrhythmia Institute
2023-2024
St. Antonius Ziekenhuis
2024
CorVita Science Foundation
2024
Liverpool Heart and Chest Hospital
2024
Medtronic (United States)
2023
Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular fibrillation. Since regulatory approval 2015, the WATCHMAN device has been only LAA closure available clinical use United States. The PINNACLE FLX study (Protection Against Embolism Nonvalvular AF Patients: Investigational Device Evaluation of Watchman Closure Technology) evaluated safety and effectiveness next-generation fibrillation whom is...
Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges achieving durable lesions. Although focal point-by-point allows the creation any required lesion set, this strategy necessitates generation contiguous lesions without gaps. A large-tip catheter, capable creating wide-footprint lesions, may increase effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent using dual...
The subcutaneous implantable cardioverter-defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the ICD cannot provide bradycardia and antitachycardia pacing. Whether modular pacing-defibrillator system comprising leadless pacemaker in wireless communication to pacing safe remains unknown.
Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk stroke. Left appendage closure a mechanical alternative to anticoagulation, but data regarding its use are lacking.
Structured Abstract Background and Aims Studies have shown correlations between early recurrence (ER) late (LR) of atrial arrhythmia after ablation with thermal technologies. This admIRE trial (NCT05293639) subanalysis aims to analyze ER versus LR in patients paroxysmal fibrillation (PAF) undergoing pulsed field (PFA). Methods Patients symptomatic ≥1 transtelephonic monitoring transmission during the blanking period were included (n=169). was defined as documented (days 1–90), evaluation...
Background: Care of heart failure (HF) patients results in a high burden on healthcare resources, and estimating prognosis is becoming increasingly important to triage resources wisely. Natriuretic peptides are recommended prognosticators chronic HF. Our objective was evaluate whether multisensor HF index alert algorithm (HeartLogic) replaces or augments current risk stratification. Methods Results: MultiSENSE (Multisensor Chronic Evaluation Ambulatory Heart Failure Patients) enrolled 900...
Background The PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman LAA [Left Atrial Appendage] Closure Technology) trial evaluated safety and efficacy a next‐generation left atrial appendage closure device (WATCHMAN FLX; Boston Scientific, Marlborough, MA). At 1 year, study met primary end points anatomical efficacy/appendage closure. This final report includes prespecified secondary point ischemic...
The comparative real-world outcomes of older patients with atrial fibrillation (AF) treated anticoagulation compared left appendage occlusion (LAAO) may be different from those in clinical trials because differences strategies and patient demographics, including a greater proportion women. We sought to compare between AF LAAO by sex.Using Medicare claims data 2015 2019, we identified LAAO-eligible beneficiaries divided them into sex subgroups. Patients receiving were matched 1:1 alone...
BACKGROUND: Evidence from clinical trials of early pulsed field ablation (PFA) systems in treating atrial fibrillation has demonstrated their promising potential to reduce complications associated with conventional thermal modalities while maintaining efficacy. However, the lack a fully integrated mapping system, staple technology most modern electrophysiology procedures, poses limitations lesion creation and workflow options. A novel variable-loop PFA catheter an electroanatomic system been...
Abstract Introduction Cryoablation therapy for pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) is well established. A novel 28 mm cryoballoon system designed operate under low pressure safely reach a lower nadir temperature and maintain constant balloon size during cooling has not been prospectively studied in large patient population safety efficacy. The FROZEN AF (NCT04133168) trial was an international multicenter, open‐label, prospective, single‐arm study on...
Percutaneous left atrial appendage (LAA) closure (LAAC) was developed as a nonpharmacologic alternative to oral anticoagulants (OACs) in patients with fibrillation (AF) who are at an increased risk for stroke or systemic embolism. The Watchman device permanently seals off the LAA prevent thrombi from escaping into circulation. Previous randomized trials have established safety and efficacy of LAAC compared warfarin. However, direct OACs (DOACs) become preferred pharmacologic strategy...
PINNACLE FLX (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the WATCHMAN LAA Closure Technology) demonstrated improved outcomes and low incidence adverse events with device in a controlled setting. The National Cardiovascular Disease Registry's Left Atrial Appendage Occlusion Registry was utilized to assess safety effectiveness contemporary clinical practice United States.
Left bundle branch area (LBBA) pacing (LBBAP) has been proposed as an alternative therapy option in patients indicated for cardiac to treat bradycardia or heart failure. The aim of the study was evaluate safety and effectiveness LBBAP implanted with a Tendril 2088 stylet-driven lead.
The clinical utilization of leadless pacemakers (LPs) as an alternative to traditional transvenous is likely increase with the advent dual-chamber LP systems. Since device retrieval allow upgrade or replacement will become important capability, first such dual-chamber, helix-fixation system (Aveir DR; Abbott, Abbott Park, IL) was specifically designed catheter-based retrieval. In this study, preclinical performance and safety retrieving chronically implanted LPs evaluated.
Four MRI variables have recently been suggested to be independently associated with a diagnosis of thoracolumbar intervertebral disk extrusion or protrusion. Midline herniation, and partial degeneration were protrusion, while presence single herniation material dispersed beyond the boundaries space extrusion. The aim this retrospective, cross‐sectional study was determine whether using these improves differentiation between extrusions protrusions. Eighty large breed dogs surgically confirmed...